Community Protocol
Retatrutide
Representative preparation math, syringe conversion, community-reported patterns and clinical-trial context.
Educational and calculation-reference material only. Community reports are uncontrolled anecdotes and do not replace professional medical guidance, product labeling, or individualized clinical monitoring.
Scope
Representative preparation math, syringe conversion, community-reported patterns and clinical-trial context.
Available strengths: 5, 10, 20, 30 and 60 MG
Preparation Examples
These are calculation examples only. The concentration assumptions below are explicit so syringe units are never separated from vial strength and diluent volume.
| Setup | Diluent | Concentration | Unit conversion |
|---|---|---|---|
| 10 MG vial – 2.0 mL example | Add 2.0 mL bacteriostatic water | 5 mg/mL | Each U-100 unit = 0.05 mg |
| 30 MG vial – 3.0 mL example | Add 3.0 mL bacteriostatic water | 10 mg/mL | Each U-100 unit = 0.10 mg |
Syringe Conversion
| Reported amount | 10 MG setup | 30 MG setup |
|---|---|---|
| 0.5 mg | 10 units | 5 units |
| 1 mg | 20 units | 10 units |
| 2 mg | 40 units | 20 units |
| 4 mg | 80 units | 40 units |
Always recalculate from the actual vial strength and diluent volume. A U-100 unit is 0.01 mL; it is not a dose by itself.
Community-Reported Patterns
| Recurring report | Frequency seen | Context in reports |
|---|---|---|
| 0.5-1 mg | Once weekly | Lower-start community reports |
| 2 mg | Once weekly | Trial-aligned starting discussions |
| 2-4 mg | Once weekly | Most recurring ongoing range reviewed |
Observations
- Community reports commonly described once-weekly administration and holding a dose for several weeks before reassessment.
- Lower 0.5-1 mg starts appeared frequently online, while the published phase 2 trial used 2 mg or 4 mg initial-dose groups depending on assignment.
- Nausea, appetite changes, gastrointestinal symptoms, fatigue and increased heart rate were recurring discussion themes.
Caveats
- Retatrutide remains investigational and is not an approved medication. Trial schedules were research protocols, not instructions for unsupervised use.
- The phase 2 trial used gradual dose escalation for higher target-dose groups; rapid increases may increase gastrointestinal and other adverse effects.